Phaseline

Targets › FN1

FN1 (Fibronectin): drug programs, companies and trials

2 programs from 1 company in 9 trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. (UniProt, P02751)

Open in Phaseline: the race on FN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PhilogenL19IL2
Fibronectin binding agent
FN1Phase 3Malignant Melanoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma …May 2028
PhilogenIL12-L19L19
Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin
IL12A, IL12B, FN1Phase 1Advanced Solid TumorDec 2026

Conditions

Locally Advanced Basal Cell Carcinoma (3) Melanoma Stage III (2) Malignant Melanoma (1) Locally Advanced Cutaneous Squamous Cell Carcinoma (1) FAP (1) Advanced Solid Tumor (1)

Modalities

small molecule (1), protein or peptide (1)

Companies

Philogen (2)

Related targets

IL12A (1) IL12B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.